(Q33425005)

English

Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

object named as

Cheolwon Suh

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Byeong-Bae Park

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Won Seog Kim

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dong-Yeop Shin

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jeong-A Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hoon-Gu Kim

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Won Sik Lee

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

8 August 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

94

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1845-1851

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Chemotherapeutic advancements in peripheral T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Treatment of refractory T-cell malignancies using gemcitabine

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplan

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Gemcitabine and cisplatin in refractory malignant lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2468-Y

21 January 2018

Identifiers

10.1007/S00277-015-2468-Y

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33425005&oldid=1953810489"